# Carboplatin and Irinotecan in Treating Children With Refractory Solid Tumors

> **NCT00024284** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb**

## Conditions studied

- Unspecified Childhood Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** carboplatin
- **DRUG:** irinotecan hydrochloride

## Key facts

- **NCT ID:** NCT00024284
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-06
- **Primary completion:** 2003-12
- **Final completion:** 2003-12
- **Target enrollment:** — (—)
- **Last updated:** 2013-04-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00024284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00024284, "Carboplatin and Irinotecan in Treating Children With Refractory Solid Tumors". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00024284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*